ENTITY

HighTide Therapeutics (1626058D HK)

4
Analysis
Health CareHong Kong
HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs.
more
14 Dec 2023 08:55

Pre-IPO HighTide Therapeutics (PHIP Updates) - Some Shareholders Have Chosen to Quit in Advance

Due to cash shortages and uncertainty in R&D/commercialization, HighTide faces big risks. Many original shareholders cashed out in advance,...

Logo
372 Views
Share
12 Nov 2023 08:08

ECM Weekly (12th Nov 2023)-Renesas, Bajaj, Alchip, Hybe, Will, Wuxi, ChaPanda, Chenqi, Cello, Honasa

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Logo
527 Views
Share
06 Nov 2023 10:10

HighTide Therapeutics (君圣泰医药) Pre-IPO: Unconvincing Bet on NASH

HighTide is looking to raise up to USD200 million via a Hong Kong listing. We analyzed the core product, HTD1801, as well as the pre-IPO investors...

Logo
341 Views
Share
11 Jul 2023 08:55

Pre-IPO HighTide Therapeutics - Its Outlook in NASH Field Is Not Optimistic, with High Risks

Intercept's failure to obtain FDA approval for NASH drug may cast shadow on HighTide's core product outlook.HighTide's valuation performance is...

Logo
331 Views
Share
No more insights
x